Chongkundang Holdings종근당홀딩스
001630 · KOSPI · ₩001630 · 종근당홀딩스
- Market cap
- ₩177B
- Enterprise value
- ₩621B
- P/E
- 3.3×
- P/B
- 0.3×
- Dividend yield
- 4.0%
- ROE
- 8.2%
- Net margin
- 5.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−36.3% from the high
₩35,000Today: ₩35,000 – ₩35,900₩55,600
Returns
- 1W−0.6%
- 1M−5.0%
- 3M−7.2%
- 6M−28.2%
- YTD−23.5%
- 1Y−23.1%
- Volume today
- 3,148
- 1.3× the 20-day average
- Traded today
- ₩111M
- Listed shares
- 5,009,861
- EPS (12 months)
- ₩10,714
- Earnings yield 30.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 46 of 100 (50 is a normal day for this stock).
- MomentumWeak-5.7% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Chongkundang Holdings stock overview
Chongkundang Holdings (종근당홀딩스, KRX: 001630) is listed on KOSPI, in the Biotech & Pharma sector. Chong Kun Dang Holdings Corp. Its shares closed at ₩35,400 on Oct 29, 2026, down 0.42% on the day, giving it a market value of ₩177B.
Key facts
- Market cap
- ₩177B
- Sector
- Biotech & Pharma
- Latest price change
- −0.42%
- As of
- Oct 29, 2026
- Main business
- Chong Kun Dang Holdings Corp.
Quick answers about Chongkundang Holdings
- What does Chongkundang Holdings do?
- Chong Kun Dang Holdings Corp. is a Korean holding company that was created in November 2013 through a spin-off, after which it holds equity stakes in its subsidiaries and affiliates, including Chong Kun Dang Pharmaceutical, Kyungbo Pharmaceutical, Chong Kun Dang Bio, and Chong Kun Dang Health. Its revenue comes mainly from management consulting fees, brand usage fees, and dividend income.
- What is the market cap of Chongkundang Holdings?
- The market capitalisation of Chongkundang Holdings was ₩177B at the close on Oct 29, 2026.
- Who are the largest shareholders of Chongkundang Holdings?
- According to the latest official filings, the largest reported holders are Lee Jang-han (48.09%, as of Sep 30, 2026); National Pension Service (4.29%, as of Apr 1, 2026); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.27%, as of Jul 31, 2026).
- When is the next earnings report from Chongkundang Holdings?
- Korean companies rarely announce results dates in advance. Based on when Chongkundang Holdings filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Chongkundang Holdings?
- Yes. The National Pension Service held 4.29% of Chongkundang Holdings shares as of Apr 1, 2026.
Company profile
Chong Kun Dang Holdings Corp. is a Korean holding company that was created in November 2013 through a spin-off, after which it holds equity stakes in its subsidiaries and affiliates, including Chong Kun Dang Pharmaceutical, Kyungbo Pharmaceutical, Chong Kun Dang Bio, and Chong Kun Dang Health. Its revenue comes mainly from management consulting fees, brand usage fees, and dividend income. Its subsidiaries operate in pharmaceuticals (ethical and OTC drugs, active pharmaceutical ingredients, and botulinum toxin), health functional foods such as probiotics and omega-3, and real estate and elderly care services, with customers including domestic and overseas pharmaceutical companies and consumers, and exports to dozens of countries.
Written by AI from the company's latest annual report.
- Korean name
- 종근당홀딩스
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 최희남
- Founded
- Jan 1956
- Listed
- Jun 1976
- Listed shares
- 5,009,861
- Fiscal year ends
- Month 12
- Website
- www.ckd-holdings.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- Amended: Half-year report (Jun 2026)Oct 12, 2026
- [Corrected] Material Matters Report (Business Suspension) (Material Management Matters of Subsidiary)Sep 30, 2026
- 5%+ holding reportSep 30, 2026
- [Corrected] Material Matters Report (Business Suspension) (Material Management Matters of Subsidiary)Aug 31, 2026
- Major management matter relevant to investorsAug 14, 2026
Titles in Korean until English translations are added.
Also known as: Chongkundang Holdings / 종근당홀딩스 / 001630 / KRX:001630
Source: KRX statistical information